EPS for Q BioMed Inc. (QBIO) forecasted at $-0.29

June 27, 2018 - By Kevin Carney

Q BioMed Inc. (OTCMKTS:QBIO) Corporate Logo

Investors expect Q BioMed Inc. (OTCMKTS:QBIO)’s quarterly earnings on July, 18., Zacks reports. Analysts expect change of 0.00 % or $0.00 from previous year’s $-0.29 earnings per share compared to current’s $-0.29 earnings per share. Wall Street now sees 70.59 % negative EPS growth despite Q BioMed Inc. last quarter’s EPS of $-0.17. QBIO is reaching $3.42 during the last trading session, after increased 0.29%.Currently Q BioMed Inc. is after 0.00% change in last June 27, 2017. QBIO has 16,791 shares volume. The stock underperformed the S&P500 by 12.57%.

Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies.The company has $47.79 million market cap. The firm offers Strontium Chloride SR89, a radiopharmaceutical agent for the treatment of pain associated with metastatic bone cancer.Currently it has negative earnings. It is also developing Man-01, a pre-clinical lead candidate for the treatment of primary open angle glaucoma.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.